Siyuan Cui

发表

Efficacy and safety of dapagliflozin in the treatment of chronic heart failure

Xuewei Yin, Xueyan Dong, Lili Ren, 2021, Medicine.

The Antagonist of CXCR1 and CXCR2 Protects db/db mice from Metabolic Diseases through Modulating Inflammation.

Fang Li, L. Qiao, Jian-ling Du, 2019, American journal of physiology. Endocrinology and metabolism.

Selenoprotein S Attenuates Tumor Necrosis Factor-α-Induced Dysfunction in Endothelial Cells

Fang Li, Jian-ling Du, Shanshan Yu, 2018, Mediators of inflammation.

CXCL8 Antagonist Improves Diabetic Nephropathy in Male Mice With Diabetes and Attenuates High Glucose–Induced Mesangial Injury

B. Wang, J. Gordon, Jyawei Cheng, 2017, Endocrinology.

Slc2a6 regulates myoblast differentiation by targeting LDHB

Y. Zhou, X. Ye, Ninghan Feng, 2022, Cell Communication and Signaling.

Efficacy and safety of dap agliflozin in the treatment of chronic heart failure A protocol for systematic review and meta-analysis

Xuewei Yin, Xueyan Dong, Yü-wen Liu, 2021 .

Apol9a regulates myogenic differentiation via the ERK1/2 pathway in C2C12 cells

Shenglong Zhu, Wei Wang, Xuan Jiang, 2022, Frontiers in Pharmacology.

Pyruvate dehydrogenase B regulates myogenic differentiation via the FoxP1–Arih2 axis

Shenglong Zhu, Wei Wang, Xuan Jiang, 2022, Journal of cachexia, sarcopenia and muscle.

Selenoprotein S regulates adipogenesis through IRE1α-XBP1 pathway.

Decheng Ren, Shi Jin, Jian-ling Du, 2019, The Journal of endocrinology.

Double knockout of FFAR4 and FGF21 aggravates metabolic disorders in mice.

Lengyun Wei, Siyuan Cui, Shenglong Zhu, 2023, International journal of biological macromolecules.